Efficacy of Fumonisin Esterase in Piglets as Animal Model for Fumonisin Detoxification in Humans: Pilot Study Comparing Intraoral to Intragastric Administration
Fumonisins, a group of highly prevalent and toxic mycotoxins, are suspected to be causal agents of several diseases in animals and humans. In the animal feed industry, fumonisin esterase is used as feed additive to prevent mycotoxicosis caused by fumonisins. In humans, a popular dosage form for diet...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-02-01
|
| Series: | Toxins |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6651/14/2/136 |
| _version_ | 1797476277832122368 |
|---|---|
| author | Kaat Neckermann Gunther Antonissen Barbara Doupovec Dian Schatzmayr James Gathumbi Véronique Delcenserie Silvio Uhlig Siska Croubels |
| author_facet | Kaat Neckermann Gunther Antonissen Barbara Doupovec Dian Schatzmayr James Gathumbi Véronique Delcenserie Silvio Uhlig Siska Croubels |
| author_sort | Kaat Neckermann |
| collection | DOAJ |
| description | Fumonisins, a group of highly prevalent and toxic mycotoxins, are suspected to be causal agents of several diseases in animals and humans. In the animal feed industry, fumonisin esterase is used as feed additive to prevent mycotoxicosis caused by fumonisins. In humans, a popular dosage form for dietary supplements, with high patient acceptance for oral intake, is capsule ingestion. Thus, fumonisin esterase provided in a capsule could be an effective strategy against fumonisin intoxication in humans. To determine the efficacy of fumonisin esterase through capsule ingestion, two modes of application were compared using piglets in a small-scale preliminary study. The enzyme was administered intraorally (in-feed analogue) or intragastrically (capsule analogue), in combination with fumonisin B1 (FB1). Biomarkers for FB1 exposure; namely FB1, hydrolysed FB1 (HFB1) and partially hydrolysed forms (pHFB1a and pHFB1b), were measured both in serum and faeces using a validated liquid chromatography-tandem mass spectrometry (LC-MS/MS) method, and toxicokinetic parameters were calculated. Additionally, the serum sphinganine/sphingosine (Sa/So) ratio, a biomarker of effect, was determined using LC-MS/MS. A significantly higher Sa/So ratio was shown in the placebo group compared to both esterase treatments, demonstrating the efficacy of the esterase. Moreover, a significant decrease in serum FB1 area under the concentration-time curve (AUC) and an increase of faecal HFB1 AUC were observed after intraoral esterase administration. However, these effects were not observed with statistical significance after intragastric esterase administration with the current sample size. |
| first_indexed | 2024-03-09T20:55:42Z |
| format | Article |
| id | doaj.art-a5c59a002b4141d0afd2e1dff3059266 |
| institution | Directory Open Access Journal |
| issn | 2072-6651 |
| language | English |
| last_indexed | 2024-03-09T20:55:42Z |
| publishDate | 2022-02-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Toxins |
| spelling | doaj.art-a5c59a002b4141d0afd2e1dff30592662023-11-23T22:21:57ZengMDPI AGToxins2072-66512022-02-0114213610.3390/toxins14020136Efficacy of Fumonisin Esterase in Piglets as Animal Model for Fumonisin Detoxification in Humans: Pilot Study Comparing Intraoral to Intragastric AdministrationKaat Neckermann0Gunther Antonissen1Barbara Doupovec2Dian Schatzmayr3James Gathumbi4Véronique Delcenserie5Silvio Uhlig6Siska Croubels7Department of Pathobiology, Pharmacology and Zoological Medicine, Faculty of Veterinary Medicine, Ghent University, Salisburylaan 133, 9820 Merelbeke, BelgiumDepartment of Pathobiology, Pharmacology and Zoological Medicine, Faculty of Veterinary Medicine, Ghent University, Salisburylaan 133, 9820 Merelbeke, BelgiumBIOMIN Research Center, Technopark 1, 3430 Tulln, AustriaBIOMIN Research Center, Technopark 1, 3430 Tulln, AustriaDepartment of Pathology, Parasitology and Microbiology, Faculty of Veterinary Medicine, University of Nairobi, P.O. Box 29053, Nairobi 00625, KenyaDepartment of Food Sciences and Fundamental and Applied Research for Animal Health (FARAH), Faculty of Veterinary Medicine, University of Liège, Avenue de Cureghem 10, 4000 Liège, BelgiumToxinology Research Group, Norwegian Veterinary Institute, P.O. Box 64, 1431 Ås, NorwayDepartment of Pathobiology, Pharmacology and Zoological Medicine, Faculty of Veterinary Medicine, Ghent University, Salisburylaan 133, 9820 Merelbeke, BelgiumFumonisins, a group of highly prevalent and toxic mycotoxins, are suspected to be causal agents of several diseases in animals and humans. In the animal feed industry, fumonisin esterase is used as feed additive to prevent mycotoxicosis caused by fumonisins. In humans, a popular dosage form for dietary supplements, with high patient acceptance for oral intake, is capsule ingestion. Thus, fumonisin esterase provided in a capsule could be an effective strategy against fumonisin intoxication in humans. To determine the efficacy of fumonisin esterase through capsule ingestion, two modes of application were compared using piglets in a small-scale preliminary study. The enzyme was administered intraorally (in-feed analogue) or intragastrically (capsule analogue), in combination with fumonisin B1 (FB1). Biomarkers for FB1 exposure; namely FB1, hydrolysed FB1 (HFB1) and partially hydrolysed forms (pHFB1a and pHFB1b), were measured both in serum and faeces using a validated liquid chromatography-tandem mass spectrometry (LC-MS/MS) method, and toxicokinetic parameters were calculated. Additionally, the serum sphinganine/sphingosine (Sa/So) ratio, a biomarker of effect, was determined using LC-MS/MS. A significantly higher Sa/So ratio was shown in the placebo group compared to both esterase treatments, demonstrating the efficacy of the esterase. Moreover, a significant decrease in serum FB1 area under the concentration-time curve (AUC) and an increase of faecal HFB1 AUC were observed after intraoral esterase administration. However, these effects were not observed with statistical significance after intragastric esterase administration with the current sample size.https://www.mdpi.com/2072-6651/14/2/136biomarkersdetoxifier administration routeefficacyfumonisin B1fumonisin esterasehuman model |
| spellingShingle | Kaat Neckermann Gunther Antonissen Barbara Doupovec Dian Schatzmayr James Gathumbi Véronique Delcenserie Silvio Uhlig Siska Croubels Efficacy of Fumonisin Esterase in Piglets as Animal Model for Fumonisin Detoxification in Humans: Pilot Study Comparing Intraoral to Intragastric Administration Toxins biomarkers detoxifier administration route efficacy fumonisin B1 fumonisin esterase human model |
| title | Efficacy of Fumonisin Esterase in Piglets as Animal Model for Fumonisin Detoxification in Humans: Pilot Study Comparing Intraoral to Intragastric Administration |
| title_full | Efficacy of Fumonisin Esterase in Piglets as Animal Model for Fumonisin Detoxification in Humans: Pilot Study Comparing Intraoral to Intragastric Administration |
| title_fullStr | Efficacy of Fumonisin Esterase in Piglets as Animal Model for Fumonisin Detoxification in Humans: Pilot Study Comparing Intraoral to Intragastric Administration |
| title_full_unstemmed | Efficacy of Fumonisin Esterase in Piglets as Animal Model for Fumonisin Detoxification in Humans: Pilot Study Comparing Intraoral to Intragastric Administration |
| title_short | Efficacy of Fumonisin Esterase in Piglets as Animal Model for Fumonisin Detoxification in Humans: Pilot Study Comparing Intraoral to Intragastric Administration |
| title_sort | efficacy of fumonisin esterase in piglets as animal model for fumonisin detoxification in humans pilot study comparing intraoral to intragastric administration |
| topic | biomarkers detoxifier administration route efficacy fumonisin B1 fumonisin esterase human model |
| url | https://www.mdpi.com/2072-6651/14/2/136 |
| work_keys_str_mv | AT kaatneckermann efficacyoffumonisinesteraseinpigletsasanimalmodelforfumonisindetoxificationinhumanspilotstudycomparingintraoraltointragastricadministration AT guntherantonissen efficacyoffumonisinesteraseinpigletsasanimalmodelforfumonisindetoxificationinhumanspilotstudycomparingintraoraltointragastricadministration AT barbaradoupovec efficacyoffumonisinesteraseinpigletsasanimalmodelforfumonisindetoxificationinhumanspilotstudycomparingintraoraltointragastricadministration AT dianschatzmayr efficacyoffumonisinesteraseinpigletsasanimalmodelforfumonisindetoxificationinhumanspilotstudycomparingintraoraltointragastricadministration AT jamesgathumbi efficacyoffumonisinesteraseinpigletsasanimalmodelforfumonisindetoxificationinhumanspilotstudycomparingintraoraltointragastricadministration AT veroniquedelcenserie efficacyoffumonisinesteraseinpigletsasanimalmodelforfumonisindetoxificationinhumanspilotstudycomparingintraoraltointragastricadministration AT silviouhlig efficacyoffumonisinesteraseinpigletsasanimalmodelforfumonisindetoxificationinhumanspilotstudycomparingintraoraltointragastricadministration AT siskacroubels efficacyoffumonisinesteraseinpigletsasanimalmodelforfumonisindetoxificationinhumanspilotstudycomparingintraoraltointragastricadministration |